Reduce oncology drug attrition rates
Predict patient respose before moving your drug to the clinic
HUB Organoids™ are unique patient-derived in vitro models developed directly from patient biopsies or resections. Our living tumor biobank includes:
- genetically stable organoid models
- a wide range of carcinoma indications
- matched primary tumor and healthy tissue-derived organoids
- organoids derived from both primary and metastatic lesions
Download our flyer
Identify responders and non-responders
Prospectively identify your target patient population and investigate the mechanism of response in patients.
Test combination strategies
Identify the most promising combo startegy with the only easily scalable patient-derived in vitro system.
Discover predictive biomarkers
Predict therapeutic outcome using models that recapitulate original patient pathophysiology and preserve patient- and cancer-specific mutations.